Detalhe da pesquisa
1.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Lancet Oncol
; 16(8): 949-56, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26179200
2.
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Breast Cancer Res Treat
; 136(3): 683-92, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23089982
3.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
J Immunother Cancer
; 10(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577503
4.
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
Sci Transl Med
; 13(598)2021 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34135110
5.
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33097612
6.
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Eur J Cancer
; 141: 162-170, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33161240
7.
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
J Immunother Cancer
; 5(1): 53, 2017 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28716061